Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Author’s Response to: Nebulised Heparin for Lung Disease: Three Overlooked Risks that Merit Study Before Chronic Clinical Use. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1007/s00408-026-00937-4 · Admitted local publication
10.1007/s00408-026-00905-y
10.1007/s00408-026-00905-y · 2026 · External reference
10.1124/pharmrev.122.000684
10.1124/pharmrev.122.000684 · 2023 · External reference
10.1128/aac.20.2.155
10.1128/aac.20.2.155 · 1981 · External reference
10.1186/s40168-017-0265-7
10.1186/s40168-017-0265-7 · 2017 · External reference
10.1186/s12931-019-1078-y
10.1186/s12931-019-1078-y · 2019 · External reference
10.1183/09031936.06.00069005
10.1183/09031936.06.00069005 · 2006 · External reference
10.1183/09031936.01.17100360
10.1183/09031936.01.17100360 · 2000 · External reference
10.1056/nejmoa1104623
10.1056/nejmoa1104623 · 2011 · External reference
10.1038/s41598-023-40489-8
10.1038/s41598-023-40489-8 · 2023 · External reference
10.1183/13993003.congress-2025.rct2287
10.1183/13993003.congress-2025.rct2287 · External reference
